StockData
Caribou Biosciences, Inc. logo

Caribou Biosciences, Inc. (CRBU) stock

CRBUNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3073% below fair value
$0.35−0.01 (-2.51%)

Close on Nov 16, 2026Market cap $37.82MP/E –Yield –

Caribou Biosciences profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Caribou Biosciences's profit margin for the twelve months ending Jun 30, 2026 was -1030.4%. For fiscal 2025 it was -1327.4%, against -1491.9% the year before. The highest annual figure on record is -277.6% in fiscal 2020.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-1327.4%+164.5
FY2024Dec 31, 2024-1491.9%−1195.9
FY2023Dec 31, 2023-296.1%+421.7
FY2022Dec 31, 2022-717.8%−20.5
FY2021Dec 31, 2021-697.3%−419.7
FY2020Dec 31, 2020-277.6%+127.3
FY2019Dec 31, 2019-404.8%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-1619.9%+408.5
Q1 FY2026Mar 31, 2026-1046.5%+653.1
Q4 FY2025Dec 31, 2025-672.1%+1036.6
Q3 FY2025Sep 30, 2025-1253.3%+460.3
Q2 FY2025Jun 30, 2025-2028.4%−940.2
Q1 FY2025Mar 31, 2025-1699.6%−2.0
Q4 FY2024Dec 31, 2024-1708.7%−738.9
Q3 FY2024Sep 30, 2024-1713.6%−1671.4
Q2 FY2024Jun 30, 2024-1088.3%−302.1
Q1 FY2024Mar 31, 2024-1697.6%−896.8
Q4 FY2023Dec 31, 2023-969.8%−238.8
Q3 FY2023Sep 30, 2023-42.3%+764.5
Q2 FY2023Jun 30, 2023-786.1%−149.3
Q1 FY2023Mar 31, 2023-800.8%−84.3
Q4 FY2022Dec 31, 2022-731.0%−8.9
Q3 FY2022Sep 30, 2022-806.8%−279.4
Q2 FY2022Jun 30, 2022-636.9%+332.7
Q1 FY2022Mar 31, 2022-716.5%+113.2
Q4 FY2021Dec 31, 2021-722.1%+772.1
Q3 FY2021Sep 30, 2021-527.4%+134.8
Q2 FY2021Jun 30, 2021-969.6%−947.5
Q1 FY2021Mar 31, 2021-829.7%−253.6
Q4 FY2020Dec 31, 2020-1494.2%–
Q3 FY2020Sep 30, 2020-662.2%–
Q2 FY2020Jun 30, 2020-22.1%–
Q1 FY2020Mar 31, 2020-576.1%–

More Caribou Biosciences figures

See a number that looks wrong?